Champions Biotechnology Begins Preclinical Development Of Its Lead Oncology Drug Candidate

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced that it has begun preclinical development of the lead Benzoylphenylurea (BPU) sulfur analog compound that the Company acquired last year. The compound has shown promising activity against in vitro and in vivo models of prostate and pancreatic cancer.

More: continued here

Filed under: Cancer on June 19th, 2008